Life Sciences & Pharmaceutical

Cut MLR Review From 40 Days to 14 Content Velocity for FDA-Regulated Markets

The pharmaceutical content bottleneck costs $60M in lost NPV for every month of delay. Transform your 6-8 week asset cycles into days.

40→14 Day Cycles
65% Cost Cut
100% Traceable
Trusted by Healthcare & Financial Services Leaders

MLR Content Review

Q1 Product Launch Campaign

Live
Review Progress 78% Complete
Reference Claims Validated

47 citations auto-verified against source documents

Done
Fair Balance Analysis

Risk/benefit ratio compliant with FDA guidelines

Done
Medical Director Review

Awaiting Dr. Chen's approval on efficacy claims

Pending
4
Final Legal Sign-off

Regulatory compliance certification

Queued
14 days
Avg. Cycle Time
65%
Faster Review
100%
Audit Trail
1

Your Data

2

AI Analysis

3

Human Approval

4

Action

The $3.1 Trillion Content Problem

After 12-15 years and billions in R&D, pharmaceutical launches are delayed by the content bottleneck. Every month of MLR delay costs $60M in net present value.

40-Day MLR Cycles

The industry average for Medical, Legal, and Regulatory review is 40 days. Legal reviewers alone average 8.2 days per asset due to competing priorities.

Every day = lost selling opportunity

$100K Per Asset

A single Digital Sales Aid costs $100K+ to produce. Rep-triggered emails cost $30K. 2,000 hours of labor annually just for creation.

500 hours/year wasted on rework

68,000+ FDA Submissions

OPDP handles 68,000+ Form 2253 submissions annually. Every claim must be annotated to specific PI pages or clinical literature.

Manual reference mapping = errors

Current Industry Benchmarks

6-8
Weeks to Create Asset
40
Days MLR Review
3.5
Review Rounds Avg
<10%
Content Reuse Rate

The Quome Content Velocity Engine

Autonomous compliance checking, modular content libraries, and AI-powered reference validation built for FDA-regulated promotional materials.

Autonomous Pre-Compliance

AI scans drafts for off-label statements, missing risk information, and fair balance issues before human review. Catch errors in real-time, not after 40 days.

Modular Content Library

Pre-approved claim modules with attached references. Build new assets by assembling validated blocks. 40%+ content reuse vs. starting from zero.

Automatic Reference Tracing

Every claim automatically mapped to PI pages, clinical studies, and source literature. 100% reference annotation for Form FDA 2253 submissions.

Concurrent MLR Workflows

Medical, Legal, and Regulatory review simultaneously instead of sequentially. Single source of truth eliminates versioning confusion.

With Quome Acceleration

1-2
Weeks to Create
14
Days MLR Review
1.2
Review Rounds
40%+
Content Reuse
65%
Reduction in Time-to-Market

The Critical Six-Month Window

80% of drug launch success is determined in the first six months. Content velocity isn't optional — it's the difference between market leadership and failure.

Launch Excellence Metrics

Pre-launch outreach impact +40% adoption
Sales + digital sync effectiveness +23% prescribing
First 6-month trajectory 80% predictor
1-month acceleration value $60M NPV

Precision Engagement at Scale

Pre-Launch Scientific Content

MSL-ready materials 18-24 months before PDUFA date

Core Launch Asset Library

OPDP-ready materials for voluntary 45-day review

Omnichannel Synchronization

Rep-triggered emails, DSAs, social — all from one modular library

Real-Time Label Updates

4-8 week agility cycles for safety or PI changes

Results That Transform Launches

Rx

Specialty Pharma Launch

Oncology Brand Launch

Before Quome

42-day average MLR cycle

3.5 review rounds per asset

$2.4M annual content spend

With Quome

14-day MLR cycle achieved

1.3 review rounds average

$840K annual content spend

Launch Impact

2 months faster to market

$120M NPV captured

Key Performance Gains

65%
Faster MLR Cycles
65%
Cost Reduction
40%+
Content Reuse
100%
Reference Coverage
$120M
NPV Captured From Acceleration
HIPAA Compliant | FDA 2253 Ready | SOC 2 In Progress

Ready to Accelerate
Your Content Velocity?

Stop losing $60M per month of delay. Transform your MLR pipeline from a 40-day bottleneck into a 14-day competitive advantage.

Enterprise pricing available. Contact us for volume licensing and custom integrations with Veeva Vault.